← Swedish Orphan Biovitrum overview

Swedish Orphan Biovitrum vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Swedish Orphan Biovitrum AB (0MTD.LSE)

Q3 2026
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

August 2026
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

Latest
▲3▼1

Sobi's profit jumps, guidance raised, and new rare-disease deals expand pipeline

  • FDA rejects gout drug NASP over manufacturing issues The FDA sent a complete response letter for Sobi's gout treatment NASP, asking for more manufacturing data. No clinical safety or efficacy problems were found, but approval is delayed. This pushes the share price down because a near-term launch is now uncertain.

    This is a fresh regulatory setback that delays a potential new product and weighs on the stock.

  • Canada backs EMPAVELI for rare kidney diseases Canada's drug agency gave a positive reimbursement recommendation for EMPAVELI in two rare kidney conditions. This opens a new market for Sobi's drug, which is already approved elsewhere. It lifts the share price by adding a new source of sales growth.

    This is a new market-access win that expands demand for an existing Sobi product.

  • Q2 profit surges and 2026 outlook raised Sobi reported much higher second-quarter profit and revenue, and raised its full-year 2026 guidance for both sales growth and profit margin. This boosts the share price because it shows the core business is performing better than expected and management is more confident.

    This is a new earnings beat and guidance raise that directly improves investor expectations for future profits.

  • Sobi-Innate lacutamab partnership becomes effective Sobi's partnership with Innate Pharma for the cancer drug lacutamab closed, triggering a $75 million payment from Sobi. The deal gives Sobi global commercial rights and a path to accelerated approval. It lifts the share price by adding a late-stage pipeline asset with blockbuster potential.

    This is a new closing of a strategic deal that expands Sobi's pipeline and future revenue prospects.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.